Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 9
2003 2
2004 2
2005 1
2006 4
2007 3
2008 3
2009 2
2010 5
2011 4
2012 3
2013 2
2015 6
2016 14
2017 11
2018 13
2019 15
2020 18
2021 14
2022 15
2023 12

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
PET/CT in Bladder Cancer: An Update.
Bouchelouche K. Bouchelouche K. Semin Nucl Med. 2022 Jul;52(4):475-485. doi: 10.1053/j.semnuclmed.2021.12.004. Epub 2022 Jan 5. Semin Nucl Med. 2022. PMID: 34996595 Free article. Review.
A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer.
Ipsen MB, Sørensen EMG, Thomsen EA, Weiss S, Haldrup J, Dalby A, Palmfeldt J, Bross P, Rasmussen M, Fredsøe J, Klingenberg S, Jochumsen MR, Bouchelouche K, Ulhøi BP, Borre M, Mikkelsen JG, Sørensen KD. Ipsen MB, et al. Among authors: bouchelouche k. Oncogene. 2022 Sep;41(37):4271-4281. doi: 10.1038/s41388-022-02427-2. Epub 2022 Aug 6. Oncogene. 2022. PMID: 35933519
Letter From the Editors.
Michael Sathekge M, Bouchelouche K. Michael Sathekge M, et al. Among authors: bouchelouche k. Semin Nucl Med. 2021 Nov;51(6):543. doi: 10.1053/j.semnuclmed.2021.06.012. Semin Nucl Med. 2021. PMID: 34602125 No abstract available.
Letter from the Editors.
Michael Sathekge M, Bouchelouche K. Michael Sathekge M, et al. Among authors: bouchelouche k. Semin Nucl Med. 2021 Jan;51(1):1-2. doi: 10.1053/j.semnuclmed.2020.09.005. Semin Nucl Med. 2021. PMID: 33246534 No abstract available.
Letter from the Editors.
Bouchelouche K, Sathekge MM. Bouchelouche K, et al. Semin Nucl Med. 2022 Jan;52(1):1-3. doi: 10.1053/j.semnuclmed.2021.08.001. Semin Nucl Med. 2022. PMID: 34865688 Free PMC article. No abstract available.
Letter from the Editors.
Bouchelouche K, Sathekge MM. Bouchelouche K, et al. Semin Nucl Med. 2022 Sep;52(5):505-507. doi: 10.1053/j.semnuclmed.2022.07.004. Semin Nucl Med. 2022. PMID: 35906038 No abstract available.
Letter from the Editors.
Sathekge MM, Bouchelouche K. Sathekge MM, et al. Among authors: bouchelouche k. Semin Nucl Med. 2022 Jul;52(4):403-405. doi: 10.1053/j.semnuclmed.2022.04.005. Semin Nucl Med. 2022. PMID: 35690428 No abstract available.
Letter from the Editors.
Bouchelouche K, Sathekge MM. Bouchelouche K, et al. Semin Nucl Med. 2022 May;52(3):263-265. doi: 10.1053/j.semnuclmed.2022.03.001. Semin Nucl Med. 2022. PMID: 35461594 No abstract available.
Letter from the Editors.
Sathekge MM, Bouchelouche K. Sathekge MM, et al. Among authors: bouchelouche k. Semin Nucl Med. 2022 Mar;52(2):91-93. doi: 10.1053/j.semnuclmed.2022.01.001. Semin Nucl Med. 2022. PMID: 35282852 No abstract available.
Letter from the Editors.
Sathekge MM, Bouchelouche K. Sathekge MM, et al. Among authors: bouchelouche k. Semin Nucl Med. 2023 Jul;53(4):467-468. doi: 10.1053/j.semnuclmed.2023.05.001. Epub 2023 May 13. Semin Nucl Med. 2023. PMID: 37188566 No abstract available.
140 results